EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A Novel KGD-Based αIIbβ3 Antagonist Prevents Arterial Thrombosis While Preserving Hemostasis and Avoiding Thrombocytopenia

Yu-Ju Kuo, Ching-Hu Chung iD, Chun-Chao Chen iD, Ju-Chi Liu, Kuan-Rau Chiou, Joen-Rong Sheu iD, Woei-Jer Chuang, Tur-Fu Huang

International Journal of Molecular Sciences · 2025

DOI: 10.3390/ijms26104530 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Yu-Ju Kuo und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiology, Department of Internal Medicine, Shuang Ho Hospital, Taipei Medical University, Taipei 23561, Taiwan. Hauptthemen laut MEDLINE: Thrombosis, Platelet Glycoprotein GPIIb-IIIa Complex, Hemostasis, Thrombocytopenia. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Science and Technology Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Current αIIbβ3 antagonists are potent antithrombotic agents, their clinical use is limited by the risk of life-threatening bleeding. Emerging evidence has highlighted key mechanistic differences between thrombosis and hemostasis, opening avenues for safer antithrombotic strategies. Targeting integrin αIIbβ3 outside-in signaling has been proposed to mitigate bleeding risk; however, the short half-life of peptide-based therapeutics remains a major challenge. In this study, we developed an optimized αIIbβ3 antagonist, KGDRR—a recombinant mutant protein derived from snake venom disintegrin, incorporating an Arg55 residue within the KGD loop—through systematic structure–activity relationship (SAR) analysis. Molecular docking revealed a critical cation–π interaction between Arg55 of KGDRR and Tyr122 of the β3 subunit, stabilizing integrin αIIbβ3 in an unliganded-closed conformation. Functionally, KGDRR selectively inhibited thrombus propagation by blocking ligand binding and downstream Gα13-mediated outside-in signaling while preserving initial thrombus core formation, which is a limitation of current αIIbβ3 inhibitors. Unlike conventional antagonists, KGDRR maintained αIIbβ3 in an unliganded-closed conformation without inducing the integrin activation and conformational change that lead to immune-mediated platelet clearance and thrombocytopenia. In animal models, KGDRR effectively suppressed thrombus growth without causing thrombocytopenia or prolonging bleeding time. Furthermore, intramuscular administration of KGDRR achieved a functional half-life 3.5 times longer than that of the clinically used antithrombotic eptifibatide at equivalent antithrombotic efficacy. In conclusion, KGDRR exhibits potent antithrombotic activity with a favorable safety profile and enhanced pharmacokinetic stability. These findings position KGDRR as a promising next generation αIIbβ3 antagonist with the potential to improve clinical outcomes in antithrombotic therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ThrombosisPlatelet Glycoprotein GPIIb-IIIa ComplexHemostasisThrombocytopeniaDisintegrinsFibrinolytic AgentsPlatelet Aggregation InhibitorsAnimalsHumansMolecular Docking SimulationMiceStructure-Activity RelationshipMaleDisease Models, Animal

Stichwörter der Autor:innen

bi-directional signalingbinding sitesdisintegrinhemorrhagic riskintegrin αIIbβ3thrombosis

Substanzen

Platelet Glycoprotein GPIIb-IIIa ComplexDisintegrinsFibrinolytic AgentsPlatelet Aggregation Inhibitors

Autor:innen und Institutionen

  • Division of Cardiology, Department of Internal Medicine, Shuang Ho Hospital, Taipei Medical University, Taipei 23561, Taiwan.
  • Department of Medicine, Mackay Medical College, New Taipei City 252, Taiwan.
  • Division of Cardiology, Department of Internal Medicine, School of Medicine, College of Medicine, Taipei Medical University, Taipei 23561, Taiwan.
  • Graduate Institute of Medical Sciences, College of Medicine, Taipei Medical University, Taipei 11031, Taiwan.
  • Department of Biochemistry, National Cheng Kung University Medical College, Tainan 701, Taiwan.
  • Graduate Institute of Pharmacology, College of Medicine, National Taiwan University, Taipei 100233, Taiwan.

ORCID-Profile: Ching-Hu Chung, Chun-Chao Chen, Joen-Rong Sheu

Förderung

  • National Science and Technology Council

Zitieren

APA

Kuo, Y. J., Chung, C. H., Chen, C. C., Liu, J. C., Chiou, K. R., Sheu, J. R., Chuang, W. J., & Huang, T. F. (2025). A Novel KGD-Based αIIbβ3 Antagonist Prevents Arterial Thrombosis While Preserving Hemostasis and Avoiding Thrombocytopenia. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26104530

Vancouver

Kuo YJ, Chung CH, Chen CC, Liu JC, Chiou KR, Sheu JR, et al. A Novel KGD-Based αIIbβ3 Antagonist Prevents Arterial Thrombosis While Preserving Hemostasis and Avoiding Thrombocytopenia. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26104530

BibTeX
@article{Kuo2025,
  author = {Kuo, Yu-Ju and Chung, Ching-Hu and Chen, Chun-Chao and Liu, Ju-Chi and Chiou, Kuan-Rau and Sheu, Joen-Rong and Chuang, Woei-Jer and Huang, Tur-Fu},
  title = {A Novel KGD-Based αIIbβ3 Antagonist Prevents Arterial Thrombosis While Preserving Hemostasis and Avoiding Thrombocytopenia},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  doi = {10.3390/ijms26104530}
}
Infokarte | EUVIMED

Artikeldaten derzeit nicht verfügbar.

Recherche